UK markets close in 2 hours 9 minutes

Ultimovacs ASA (ULTIO.OL)

Oslo - Oslo Delayed price. Currency in NOK
Add to watchlist
70.300.00 (0.00%)
As of 02:19PM CEST. Market open.
Full screen
Previous close70.30
Open70.30
Bid65.00 x N/A
Ask0.00 x N/A
Day's range70.30 - 70.30
52-week range70.30 - 70.30
Volume150
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation

    Oslo, 12 August 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its second quarter 2022 results on Friday 19 August 2022. The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 09:00 CET on Friday 19 August 2022. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation th

  • Globe Newswire

    Ultimovacs ASA: Mandatory notification of trade by primary insider

    Oslo, 30 June 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of NOK 69.50 per share. Following this transaction, Carlos de Sousa and closely related parties hold 18,056 shares and 416,035 share options in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Secu

  • Globe Newswire

    Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

    Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 monthsStudy provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces the completed recruitment of 154 patients in the INITIUM trial. INITIUM is Ultimovacs’ Phase II clinical trial of its universal cancer